HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda


— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —

More here:
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Related Posts